SCHEMBL7189231

SCHEMBL7189231

COc1cccc(Cl)c1C(=O)[PH](=O)c1c(C)c(C)c(C(=O)c2ccccc2)c(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FABP4 P15090 1/20 0.40
MAPT P10636 5/20 0.38
LMNA P02545 3/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
RORC P51449 1/20 0.38
ATM Q13315 1/20 0.37
TUBB4A P04350 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7184922 0.98 RAB9A (0.39) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7187754 0.91 CA12 (0.45) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7174982 0.91 TUBB4A (0.40) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7181661 0.89 CA12 (0.43) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7188863 0.89 ALDH1A1 (0.44) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL7180562 0.87 MAPT (0.39) RAB9AKMT2AMEN1NPC1SMN1; SMN2
SCHEMBL7180790 0.87 CA12 (0.41) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7182828 0.86 MEN1 (0.40) RAB9AKMT2AMEN1CA12CA1
SCHEMBL7175608 0.86 ALDH1A1 (0.42) KMT2AMEN1MAPTLMNAALDH1A1
SCHEMBL7175667 0.85 MAPT (0.41) RAB9AKMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 RAB9A 1818/4885KMT2A 1586/4885MEN1 2312/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 RAB9A 2155/4885KMT2A 956/4885MEN1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.